- Total grants
- Total funders
- Total recipients
- Earliest award date
- 17 Oct 2005
- Latest award date
- 30 Sep 2020
- Total GBP grants
- Total GBP awarded
- Largest GBP award
- Smallest GBP award
- Total Non-GBP grants
This grant will support both Sheffield Hallam University and the National Foundation for Educational Research (NFER) to work with the four grantees of the Teacher Research Scoping Grants and to undertake the writing and costing of the proposal for the research and evaluation study of this programme.
Determining Preferred Product Characteristics to Support Uptake of Innovative Antibodies 30 Sep 2020
Through this project, IAVI and WHO Immunizations, Vaccines, and Biologicals (IVB) will harness input from a broad network of stakeholders to produce a Preferred Product Characteristics (PPC) technical document for forthcoming monoclonal antibodies (mAbs) for HIV prevention. Created early in clinical development and with attentiveness to end-user and health systems perspectives, this PPC document will provide strategic guidance as to preferences for new HIV preventative antibodies to inform clinical development and support eventual integration into WHO policy. While the focus of this effort will be on articulating optimal product attributes for antibodies for HIV prophylaxis, it is anticipated that acceptability, suitability and feasibility criteria identified through this process can inform product design, clinical development, and access considerations for a broader array of antibody-based products for infectious and neglected diseases in the pipeline.
lvermectin Safety in Small Children 30 Sep 2020
lvermectin is a very safe and beneficial drug which is used for the treatment of more than a dozen different neglected tropical diseases (NTDs), many of which are associated with important public health problems. Current label indications for ivermectin prevent use in small children weighing less than 15kg, due to limited safety data in this group. Many of the NTD treatment options for small children rely on compounds that are less safe and/or efficacious compared to oral ivermectin. Our proposal will establish the safety and pharmacokinetics of escalating doses of ivermectin to treat scabies infected children weighing less than 15kg. The safety assessment will provide crucial evidence on the use of ivermectin for numerous diseases in children weighing less than 15kg. The information from measuring drug concentrations in the patients will inform the optimal dosing of this drug in small children. Assessment of the efficacy of ivermectin, compared to permethrin cream, for the treatment of scabies in small children can provide an important alternative treatment for this widespread disease.
Strengthening research ethics systems in Latin America and the Caribbean This proposal of the Regional Program on Bioethics of the Pan American Health Organization (PAHO) aims at significantly improving the regional research ethics landscape and, specifically, at strengthening research ethics systems and enhancing ethics preparedness to conduct research during emergencies. In response to a 2018 explicit request from the countries in the Americas to advance research ethics with a systemic approach, PAHO’s Regional Program on Bioethics developed indicators and a strategy to address the regional challenges. While this action has already triggered progress rapidly in few countries (e.g. Peru), PAHO’s resources to scale up these efforts as requested by the countries are very limited. This grant would allow PAHO to (a) assess the current situation using indicators, (b) advance change in several countries in Latin America and the Caribbean using national research ethics policies as a strategy, (c) support the implementation of such policies through an online tool for ethics review, and (d) share this model so it can be replicated by other regions. PAHO is uniquely positioned to achieve these outcomes due to its ongoing work supporting national health authorities on bioethics.